IP Library Granted Patent US 10,874,665
Granted Patent B2
US 10,874,665 · App. 16/823,807 · Granted Dec 29, 2020

Bupropion as a modulator of drug activity

Inventor: Herriot Tabuteau (New York, NY)
Assignee: ANTECIP BIOVENTURES II LLC
A61K31/485A61K9/0053A61K31/135A61K31/137A61K31/15A61K31/343A61K31/381
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,665
App. No.
16/823,807
Granted
Dec 29, 2020
Kind
B2
Abstract

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Claims (15)

1. A method of treating depression, comprising administering a drug combination comprising: a daily dose of bupropion that is about 150 mg to about 250 mg and a daily dose of dextromethorphan that is about 60 mg to about 100 mg, to a human being in need thereof for at least 8 consecutive days, wherein the bupropion and the dextromethorphan are present in a dosage form, wherein the bupropion and the dextromethorphan are the only therapeutically active compounds in the dosage form; wherein administering the drug combination is more effective in treating depression than administering the same daily dose of the bupropion alone wherein the daily doses of the bupropion and the dextromethorphan are orally administered once a day or are a total of twice daily doses; and wherein the dosage form is formulated for immediate release of dextromethorphan and sustained release of bupropion.

2. The method of claim 1 , wherein administering the drug combination is more effective in treating depression than administering the same daily dose of the dextromethorphan alone.

3. The method of claim 1 , wherein the daily dose of the bupropion is administered once daily and the daily dose of the dextromethorphan is administered once daily.

4. The method of claim 1 , wherein one half of the daily dose of the bupropion is administered twice daily and one half of the daily dose of the dextromethorphan is administered twice daily.

5. The method of claim 1 , wherein the drug combination is administered for at least 14 consecutive days.

6. The method of claim 1 , wherein the drug combination is administered for at least 30 consecutive days.

7. The method of claim 1 , wherein the weight ratio of the dextromethorphan to the bupropion in the drug combination is about 0.3 to about 0.5.

8. The method of claim 1 , wherein the drug combination is administered orally.

9. The method of claim 1 , wherein the dosage form is a solid dosage form.

10. The method of claim 1 , wherein the human being has a C avg of bupropion that is at least about 10 ng/mL after the drug combination is administered.

11. The method of claim 1 , wherein the human being has a C max of bupropion that is at least about 90 ng/mL after the drug combination is administered.

12. The method of claim 1 , wherein the drug combination comprises: a daily dose of bupropion hydrochloride that is about 210 mg and a daily dose of the dextromethorphan that is about 60 mg to about 100 mg.

13. The method of claim 12 , wherein administering the drug combination is more effective in treating depression than administering 105 mg of bupropion hydrochloride twice a day for the same number of consecutive days.

14. The method of claim 1 , wherein the depression is major depressive disorder.

15. The method of claim 1 , wherein the depression is treatment-resistant depression.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2020
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 052553/0774 →
Continuity (12)
Continuation In Part 16359958 · Mar 20, 2019
Continuation In Part 15821563 · Nov 22, 2017
Continuation In Part 15645939 · Jul 10, 2017
Continuation In Part 15263138 · Sep 12, 2016
Continuation 15164746 · May 25, 2016
Continuation In Part 14879002 · Oct 8, 2015
Continuation 14554988 · Nov 26, 2014
Continuation 14550618 · Nov 21, 2014
Continuation In Part PCTUS2014064184 · Nov 5, 2014
Provisional Application 62576538 · Oct 24, 2017
Provisional Application 61900354 · Nov 5, 2013
Related Publication 20200215058A1 · Jul 9, 2020
Cited By (25)
US 12,194,005 US 12,194,006 US 12,194,036 US 12,239,642 US 12,263,161 US 12,310,961 US 12,357,697 US 12,364,674 US 12,370,154 US 12,377,091 US 12,390,428 US 12,433,884 US 12,447,138 US 12,472,155 US 12,472,156 US 12,472,174 US 12,478,622 US 12,544,345 US 12,564,587 US 12,569,479 US 12,576,078 US 12,599,576 US 12,653,795 US 12,661,408 US 12,678,506